Compare Anheuser-Busch Inbev SA (BUD) vs GSK plc (GSK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Anheuser-Busch Inbev SA vs GSK plc — how do they compare? Anheuser-Busch Inbev SA trades at $78.98 (market cap $153.45B), while GSK plc trades at $51.21 (market cap $101.55B). The key difference: Anheuser-Busch Inbev SA is the larger of the two by market cap, and GSK plc pays the higher dividend (3.5%). Which is the better fit depends on your goals.
| BUD | GSK | |
|---|---|---|
Market Cap | $153.45B | $101.55B |
Sector | Consumer Staples | Health |
52-Week High | $85.09 | $61.18 |
52-Week Low | $57.10 | $36.20 |
Enterprise Value | $214.64B | $122.16B |
Dividend Yield | 1.7% | 3.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BUD trades at $79.33, down 0.35% with bearish technical signals. The company demonstrates solid fundamentals with consistent earnings beats, 11.9% net margin, and improving cash flow. Recent dividend payment of $1.17 and positive analyst sentiment with 57.8% buy ratings support the investment case. Premiumization strategy and digital expansion drive growth amid changing consumer preferences.
Outlook remains positive with $90.08 consensus price target offering 13.5% upside. Key risks include alcohol moderation trends and competitive pressures. Strong balance sheet with declining debt-to-asset ratio to 33.9% provides financial stability. Revenue growth expected to accelerate to $61B in 2026 with expanding margins.
GSK trades at $52.29, down 0.93% with neutral technical signals. The company shows strong fundamentals with Q1 2026 EPS beating expectations at $1.24 versus $1.16 forecast. Recent FDA approvals for Utebzi and positive Jemperli trial results highlight pipeline strength. Valuation metrics appear reasonable with P/E of 13.94 and ROE of 36.42%.
GSK presents a balanced investment case with solid profitability and promising drug pipeline offset by mixed analyst sentiment and competitive pressures. The stock offers income potential with 3.46% dividend yield but faces execution risks in drug development and market competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Anheuser-Busch Inbev SA
Anheuser-Busch InBev is the largest brewer in the world and one of the world's top five consumer product companies, as measured by EBITDA. After the SABMiller acquisition, the company's portfolio now contains five of the top 10 beer brands by sales and 18 brands with retail sales over $1 billion. AB InBev was created by the 2008 merger of Belgium-based InBev and U.S.-based Anheuser-Busch. The firm holds a 62% economic interest in Ambev and in 2016 acquired SABMiller.
Read more on BUD →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
